Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • MarketBeat previews the top five stocks to own by March 1st.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.2929 of 5 stars
$22.25-1.2%N/A-8.06Moderate Buy$38.00
Ultragenyx Pharmaceutical (RARE)
4.5606 of 5 stars
$45.35-0.9%N/A-7.01Moderate Buy$92.43
Sarepta Therapeutics (SRPT)
4.7413 of 5 stars
$111.82-0.3%N/A89.46Moderate Buy$178.71
Pfizer (PFE)
4.9798 of 5 stars
$25.76-0.3%6.68%18.27Moderate Buy$31.92
Exelixis (EXEL)
4.5419 of 5 stars
$33.48-0.6%N/A21.46Moderate Buy$36.06
Moderna (MRNA)
4.5665 of 5 stars
$32.60-3.0%N/A-5.60Hold$67.26
United Therapeutics (UTHR)
4.4797 of 5 stars
$347.71-1.7%N/A15.27Moderate Buy$382.08
Biogen (BIIB)
4.6697 of 5 stars
$141.35-0.7%N/A12.77Hold$228.80
Sanofi (SNY)
3.8064 of 5 stars
$53.35+0.9%2.76%21.43Buy$60.00
Eli Lilly and Company (LLY)
4.9848 of 5 stars
$878.09+0.9%0.59%74.99Moderate Buy$997.50
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

AMD Stock’s Big Drop: Buy the Dip or More Pain Ahead?
Index Investing for Beginners
7 Inflation-Proof Stocks to Protect Your Portfolio

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines